Experience with the use of gelatin tannate in complex therapy in patients with a new coronavirus infection COVID-19

The new coronavirus infection COVID-19 is a systemic disease associated with the involvement in the pathological process not only of the lungs with the development of respiratory failure, but also of cells of the gastrointestinal tract, which causes dysbiosis of the intestinal microbiota, thereby contributing to the development of interstitial inflammation in the intestinal wall. The purpose of our research was to evaluate the effectiveness of the use of the gelatin tannate in intestinal lesions in patients with a new coronavirus infection COVID-19. The study included 58 patients diagnosed with a new coronavirus infection COVID-19 aged 35 to 70 years, hospitalized in the infectious hospital of the State Autonomous Healthcare Institution of the Sverdlovsk region "City Clinical Hospital No. 40" of Yekaterinburg. The patients were divided into 2 groups: the main group (n = 26) of people who received gelatin tannate in the complex therapy, the second group (control, n = 32) who did not receive the cytomucoprotector Adiarin in the complex therapy. The study included the patients with COVID-19 infection with gastrointestinal manifestations confirmed by the results of the analysis of a smear from the nasopharynx and oropharynx for SARS-CoV-2 coronavirus by polymerase chain reaction. The exclusion criteria from the study were age over 70 years, concomitant pathology: diseases of the musculoskeletal system, chronic kidney disease, pregnancy, infection caused by the human immunodeficiency virus, oncohematological and lymphoproliferative diseases. Against the background of taking of gelatin tannate, the following phenomena were observed in the main group in comparison with the control group: a decrease in the duration of febrile syndrome by 1.2 times, diarrheal syndrome by 2.5 times, dyspeptic syndrome by 1.8 times; correlation between the frequency and duration of diarrheal syndrome and the severity of interstitial inflammation in the intestinal wall (r = 0.7, p < 0.01); immunomodulatory effect on the T-cell link of immunity. No side effects were observed.

1. Ojetti V., Saviano A., Covino M., et al. COVID-19 and intestinal inflammation: Role of fecal calprotectin // Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2020; 52 (11): 1231-1233. DOI:10.1016/j.dld.2020.09.015.

2. Aktas B., Aslim B. Gut-lung axis and dysbiosis in COVID-19 // Turkish Journal of Biology. 2020; 44 (3): 265-272. Published 2020 Jun 21. DOI:10.3906/biy-2005-102.

3. Giron L. B., Dweep H., Yin X., et al. Plasma Markers of Disrupted Gut Permeability in Severe COVID-19 Patients [published correction appears in Front Immunol. 2021 Oct 04; 12: 779064]. // Front Immunol. 2021; 12: 686240. Published 2021 Jun 9. DOI:10.3389/fimmu.2021.686240.

4. Zuo T., Zhang F., Lui G. C. Y., et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization // Gastroenterology. 2020; 159 (3): 944-955. DOI:10.1053/j.gastro.2020.05.048.

5. Khasaeva E. I., Deulina L. E. Antidiarrhealdrugs // Innovations. The science. Education. 2021; 48: 2567-2570.

6. Bingula R., Filaire M., Radosevic-Robin N., et al. DesiredTurbulence? GutLung Axis, Immunity, and Lung Cancer // J Oncol. 2017; 2017: 5035371. DOI:10.1155/2017/5035371.

7. Samuelson D. R., Welsh D. A., Shellito J. E. Regulation of lung immunity and host defense by the intestinal microbiota // Front Microbiol. 2015; 6: 1085. Published 2015 Oct 7. DOI:10.3389/fmicb.2015.01085.

8. Huffnagle G. B. The microbiota and allergies/asthma // PLoSPathog. 2010; 6 (5): e1000549. Published 2010 May 27. DOI:10.1371/journal.ppat.1000549.

9. Gao Q. Y., Chen Y. X., Fang J. Y. 2019 Novel coronavirus infection and gastrointestinal tract // The Journal of Digestive Diseases. 2020; 21 (3): 125-126. DOI:10.1111/1751-2980.12851.

10. Gu J., Han B., Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission // Gastroenterology. 2020; 158 (6): 1518-1519. DOI:10.1053/j.gastro.2020.02.054.

11. Hashimoto T., Perlot T., Rehman A., et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation // Nature. 2012; 487 (7408): 477-481. Published 2012 Jul 25. DOI:10.1038/nature11228.

12. Mori A., Mitsuyama K., Sakemi R., et al. Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease // Kurume Med J. 2021; 66 (4): 209-215. DOI:10.2739/kurumemedj.MS664009.

13. Kyle B. D., Agbor T. A., Sharif S., et al. Fecal Calprotectin, CRP and Leucocytes in IBD Patients: Comparison of Biomarkers WithBiopsy Results // J Can Assoc Gastroenterol. 2020; 4 (2): 84-90. Published 2020 Mar 27. DOI:10.1093/jcag/gwaa009.

14. Kim J., Kim H., Oh H. J., et al. Fecal Calprotectin Level Reflects the Severity of Clostridium difficile Infection // Ann Lab Med. 2017; 37 (1): 53-57. DOI:10.3343/alm.2017.37.1.53.

15. Temporary guidelines. Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19), version 10 (02/08/2021) / Avdeev S. N., Adamyan L. V., Alekseeva E. I. and others.

16. Temporary guidelines. Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19), version 11 (05/07/2021) / Avdeev S. N., Adamyan L. V., Alekseeva E. I. and others.

17. Charlson M. E., Pompei P., Ales K. L., McKenzie C. R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation // J Chron Dis. 1987; 40 (5): 373-383.

18. Khavkina D. A., Ruzhentsova T. A., Popova R. V. I., et al. The effectiveness of pathogenetic therapy for infectious diarrhea in children during the COVID-19 epidemic // Medical Council. 2020; 2: 95-100.